tiprankstipranks
Advertisement
Advertisement
Cogent Biosciences announces preclinical data from KRAS, ErbB2 programs
PremiumThe FlyCogent Biosciences announces preclinical data from KRAS, ErbB2 programs
3M ago
Bezuclastinib’s Strong Phase 3 GIST Data and NDA Catalyst Support Buy Rating and $52 Target
Premium
Ratings
Bezuclastinib’s Strong Phase 3 GIST Data and NDA Catalyst Support Buy Rating and $52 Target
4M ago
Cogent Biosciences submits bezuclastinib new drug application to the FDA
Premium
The Fly
Cogent Biosciences submits bezuclastinib new drug application to the FDA
4M ago
Cogent Biosciences price target raised to $35 from $34 at Baird
PremiumThe FlyCogent Biosciences price target raised to $35 from $34 at Baird
5M ago
Buy Rating Backed by Bezuclastinib’s Late-Stage Catalysts, Dual-Launch Potential, and Differentiated Profile in GIST and SM
Premium
Ratings
Buy Rating Backed by Bezuclastinib’s Late-Stage Catalysts, Dual-Launch Potential, and Differentiated Profile in GIST and SM
5M ago
Cogent Biosciences price target raised to $52 from $39 at Piper Sandler
Premium
The Fly
Cogent Biosciences price target raised to $52 from $39 at Piper Sandler
5M ago
Cogent Biosciences announcse U.S. BTD for bezuclastinib
PremiumThe FlyCogent Biosciences announcse U.S. BTD for bezuclastinib
6M ago
Cogent Biosciences Expands HER2 Oncology Footprint With New Early-Stage CGT4255 Trial
Premium
Company Announcements
Cogent Biosciences Expands HER2 Oncology Footprint With New Early-Stage CGT4255 Trial
6M ago
Cogent to initiate New Drug Application submission for bezuclastinib
Premium
The Fly
Cogent to initiate New Drug Application submission for bezuclastinib
6M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100